NetworkNewsBreaks – BriaCell Therapeutics Corp. (TSX.V: BCT) (OTCQB: BCTXF) Details Proposed Financing Deals Valued at Up to $4.8M
Immuno-oncology focused biotechnology company BriaCell Therapeutics Corp. (TSX.V: BCT) (OTCQB: BCTXF) recently announced plans to enter into a securities purchase agreement of convertible notes with a leading group of biotech-focused institutional and family office funds for an investment of $800,000. Under the terms of the proposed agreement, the note offering will consist of a five percent unsecured convertible note of BriaCell in the principal amount of $800,000 which will be convertible at the option of the holder into common shares of BriaCell at a fixed conversion price of C$0.10 per common share. The offering will also include one common share…







